Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHANNON E BABINEAU

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology with Special Qualifications in Child Neurology

NPI
1538370630
CMS profile
296448
Location
MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$49.06

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $49.06 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $49.06 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHANNON E BABINEAU

NPI 1538370630 · CMS profile ID 296448

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology with Special Qualifications in Child Neurology

MORRISTOWN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538370630?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHANNON E BABINEAU, NPI 1538370630, CMS profile ID 296448. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538370630?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHANNON E BABINEAU, NPI 1538370630, CMS profile ID 296448. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538370630?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHANNON E BABINEAU, NPI 1538370630, CMS profile ID 296448, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538370630?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $49.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $16.6611/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201452189 CMS
ABBVIE INC. $16.4010/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201452187 CMS
ABBVIE INC. $16.0002/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201452185 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $360.40 8
PY2021 $477.18 17
PY2022 $106.65 6
PY2023 $173.57 8
PY2024 $173.86 9
PY2025 $49.06 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $84,688.05 44
PY2024 Principal investigator $30,525.69 15
PY2023 Principal investigator $72,275.11 13
PY2022 Principal investigator $51,540.63 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416668
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202416671
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202416673
Principal investigator 1 ABBVIE INC. $450.00 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416677
Principal investigator 1 ABBVIE INC. $450.00 12/31/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416681
Principal investigator 1 ABBVIE INC. $2,438.38 12/04/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416657
Principal investigator 1 ABBVIE INC. $82.35 11/26/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416653
Principal investigator 1 ABBVIE INC. $339.00 11/20/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416643
Principal investigator 1 ABBVIE INC. $339.00 11/20/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416647
Principal investigator 1 ABBVIE INC. $1,153.00 10/09/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416635
Principal investigator 1 ABBVIE INC. $435.11 10/09/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416639
Principal investigator 1 ABBVIE INC. $450.00 10/02/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416633
Principal investigator 1 ABBVIE INC. $450.00 09/26/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416628
Principal investigator 1 ABBVIE INC. $450.00 09/25/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416625
Principal investigator 1 ABBVIE INC. $628.00 09/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416617
Principal investigator 1 ABBVIE INC. $2,315.12 09/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416621
Principal investigator 1 ABBVIE INC. $450.00 08/21/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416608
Principal investigator 1 ABBVIE INC. $450.00 08/21/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416612
Principal investigator 1 ABBVIE INC. $450.00 08/05/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416597
Principal investigator 1 ABBVIE INC. $628.00 08/05/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416601
Principal investigator 1 ABBVIE INC. $870.22 08/05/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416605
Principal investigator 1 ABBVIE INC. $1,846.00 07/02/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416592
Principal investigator 1 ABBVIE INC. $2,003.27 06/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416574
Principal investigator 1 ABBVIE INC. $1,781.00 06/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416577
Principal investigator 1 ABBVIE INC. $5,250.00 05/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416553
Principal investigator 1 ABBVIE INC. $8,055.00 05/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416557
Principal investigator 1 ABBVIE INC. $2,250.00 05/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416562
Principal investigator 1 ABBVIE INC. $1,000.00 05/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416565
Principal investigator 1 ABBVIE INC. $7,605.00 05/27/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416569
Principal investigator 1 ABBVIE INC. $5,708.00 05/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416534
Principal investigator 1 ABBVIE INC. $435.11 05/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416537
Principal investigator 1 ABBVIE INC. $628.00 05/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416541
Principal investigator 1 ABBVIE INC. $5,708.00 05/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416545
Principal investigator 1 ABBVIE INC. $3,543.00 05/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416549
Principal investigator 1 ABBVIE INC. $3,247.00 04/24/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416526
Principal investigator 1 ABBVIE INC. $3,543.00 04/24/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416531
Principal investigator 1 ABBVIE INC. $2,352.99 04/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416519
Principal investigator 1 ABBVIE INC. $1,670.63 04/03/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416523
Principal investigator 1 ABBVIE INC. $3,543.00 03/13/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416511
Principal investigator 1 ABBVIE INC. $1,784.93 03/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416499
Principal investigator 1 ABBVIE INC. $2,678.94 03/06/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202416503
Principal investigator 1 ABBVIE INC. $1,176.00 02/05/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416487
Principal investigator 1 ABBVIE INC. $1,495.00 01/02/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M21-201 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416479
Principal investigator 1 ABBVIE INC. $1,916.00 01/02/2025 Covered Recipient Teaching Hospital
MORRISTOWN MEDICAL CENTER
M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202416482